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Abstract
Background/Aims: Several countries are working to adapt clinical trial regulations to align the approval process to the
level of risk for trial participants. The optimal framework to categorize clinical trials according to risk remains unclear,
however. Switzerland is the first European country to adopt a risk-based categorization procedure in January 2014. We
assessed how accurately and consistently clinical trials are categorized using two different approaches: an approach using
criteria set forth in the new law (concept) or an intuitive approach (ad hoc).
Methods: This was a randomized controlled trial with a method-comparison study nested in each arm. We used clinical
trial protocols from eight Swiss ethics committees approved between 2010 and 2011. Protocols were randomly assigned
to be categorized in one of three risk categories using the concept or the ad hoc approach. Each protocol was indepen-
dently categorized by the trial’s sponsor, a group of experts and the approving ethics committee. The primary outcome
was the difference in categorization agreement between the expert group and sponsors across arms. Linear weighted
kappa was used to quantify agreements, with the difference between kappas being the primary effect measure.
Results: We included 142 of 231 protocols in the final analysis (concept = 78; ad hoc = 64). Raw agreement between
the expert group and sponsors was 0.74 in the concept and 0.78 in the ad hoc arm. Chance-corrected agreement was
higher in the ad hoc (kappa: 0.34 (95% confidence interval = 0.10–0.58)) than in the concept arm (0.27 (0.06–0.50)), but
the difference was not significant (p = 0.67).
Limitations: The main limitation was the large number of protocols excluded from the analysis mostly because they
did not fit with the clinical trial definition of the new law.
Conclusion: A structured risk categorization approach was not better than an ad hoc approach. Laws introducing risk-
based approaches should provide guidelines, examples and templates to ensure correct application.
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Introduction
In recent years, the increasing costs and administrative
complexity of clinical research,1–5 as well as concerns
about the shift of clinical trials from wealthy countries
to less wealthy countries,6–8 have given rise to initia-
tives to revise the legal framework within which clinical
research is conducted. The goal of these initiatives is to
harmonize the clinical research processes, reduce the
bureaucratic burden, lower the costs and better protect
human beings participating in clinical trials.9–11 They
recommend introducing so-called risk-based
approaches to adapt regulatory requirements based on
the risk associated with participation in clinical trials.
Risk-based approaches have so far been used to guide
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on-site monitoring and quality assurance processes in
the conduct of clinical trials.12,13 Nevertheless, the opti-
mal framework for categorizing clinical trials according
to their risks and the respective regulatory conse-
quences remain unclear.
Two recent initiatives, one from the Organisation for
Economic Co-operation and Development (OECD)
working group and the other from a joint project of the
Medical Research Council (MRC) and Medicines and
Healthcare Products Regulatory Agency (MHRA), rec-
ommend introducing risk categories for clinical trials of
investigational medicinal products in the regulatory
framework.10,14,15 Furthermore, they propose adapting
regulatory requirements for approval and conduct
according to the risk category. Based on the marketing
authorization status of the investigational medicinal
product tested in the clinical trial, the OECD recom-
mendations define three categories of clinical trials: A
(lowest risk category), B and C (highest risk category).14
The MHRA approach defines three types of clinical
trials according to the risk associated with the investiga-
tional medicinal product compared with standard medi-
cal care: A (no higher), B (somewhat higher) and C
(markedly higher).15
The UK government has endorsed the concept of
regulatory requirements proportionate to risk.16
Furthermore, the European Union (EU) elaborated a
new Clinical Trial Regulation17 which introduces risk
categories for clinical trials compatible with those rec-
ommended by the OECD.14 Likewise, the United
States is working to adapt their clinical trial regulations
to align the complexity of the approval process with the
risk to the participants.18,19 Switzerland became the
first European country to adopt a risk-based legislation
for clinical trials.20–22 A parliamentary motion man-
dated the Swiss Federal Council to introduce a federal
act to harmonize pre-existing cantonal legislations on
human research.23 Consequently, a new article added
to the Constitution provided the legal framework to
regulate human research according to the risk to which
participants are exposed.24 To be compatible with other
international initiatives, Switzerland broadly followed
the OECD recommendations.14 The draft Clinical
Trials Ordinance which defines criteria to categorize
clinical trials was released to public consultation
between 31 August and 31 October 2012.25 Online
Appendix 1a compares the clinical trial categories
defined in the draft Clinical Trials Ordinance with the
EU regulation and those of the OECD and MHRA. In
contrast to the EU regulation and the OECD and
MHRA initiative, the draft Clinical Trials Ordinance
regulates clinical trials involving any type of interven-
tion and not only drugs or devices. Online Appendix 1b
presents the risk categories for clinical trials with medi-
cal devices and non-pharmacological/non-device inter-
ventions. The new regulation does not establish a
concept of minimal risk, and it does not consider
‘standard care’ as a principle for categorization. The
draft Clinical Trials Ordinance categorization approach
is based on two principles: (1) the marketing authoriza-
tion status in Switzerland for drugs and medical devices
and (2) whether the use of the investigated intervention
falls within the specified summary of product character-
istics (for drugs), Conformite´ Europe´enne (CE) mark
specifications (for medical devices) or established medi-
cal guidelines (for non-pharmacological and non-device
interventions). Drugs or devices with marketing author-
ization are assumed to have been tested and their use
authorized by competent authorities so that potential
risks related to the use of such medicinal products are
reasonable for trial participants when used according
to their (approved) specifications. Similarly, the risk of
non-pharmacological/non-device interventions is
assumed reasonable when used as indicated in an estab-
lished medical guideline. Based on these principles, the
sponsor has to classify the clinical trial into one of three
categories (A, B or C). Each category implies different
regulatory requirements for approval, conduct, insur-
ance and safety reporting.20,26,27 Category A represents
the category with the fewest and category C the one
with the most regulatory requirements.
In this study, we tested the consistency and applic-
ability of the criteria for categorization of clinical trials
outlined in the draft Clinical Trials Ordinance.25 For
this purpose, we used a randomized controlled trial
with a method-comparison study nested in each arm.
We assessed how consistently clinical trials were cate-
gorized using the draft Clinical Trials Ordinance criteria
(concept) compared to an intuitive, ad hoc approach
without pre-specified criteria (ad hoc). We compared
the categorization agreement between categorizing per-
sons using the concept approach with the categorization
agreement between categorizing persons using the ad
hoc approach. Finally, we identified qualitative aspects
related to the applicability of the categorization proce-
dure and recommendations for implementation of simi-
lar legislations in the future. The results of this study
served to inform policy-makers prior implementation of
the Ordinance.
Methods
Study design
This was a two-arm randomized controlled trial with a
method-comparison study nested in each arm. In one
arm, different types of categorizing persons (assessors)
used the risk-based categorization approach outlined in
the new draft Clinical Trials Ordinance to categorize
clinical trial protocols (concept). In the other arm,
assessors used an unstructured, intuitive approach (ad
hoc). The categories were the same in both arms; only
the categorization procedure itself, that is, the guidance
on how to arrive at the respective category, was
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different. We compared the categorization agreement
among assessors between arms and within arms. We
hypothesized that structured pre-defined criteria (con-
cept) would lead to more consistent categorizations as
compared to unstructured categorizations and conse-
quently better agreement between assessors.
Concept categorization procedure
In the concept arm, assessors used a web-based,
decision-tree questionnaire built with the categorization
criteria defined in the draft Clinical Trials Ordinance.
No specific training was provided besides a written gen-
eral introduction. The criteria and number of applica-
ble categories varied depending on three main aspects:
first, the type of intervention studied, that is, drugs,
medical devices or non-pharmacological/non-device
intervention; second, the approval status in Switzerland
for drugs and medical devices; and third, whether the
intervention was used according to the summary of
product characteristics in case of drugs, the CE mark
specifications in case of medical devices or established
medical guidelines in case of non-pharmacological/
non-device interventions. Accordingly, assessors
applied different categories: A, B or C for clinical trials
with drugs; A or C for clinical trials with medical
devices; and A or B for clinical trials with non-pharma-
cologic/non-device interventions. Category A repre-
sents the lowest and C the highest risk category. In case
of clinical trials with mixed interventions (e.g. drug and
device investigated in the same trial), each intervention
was first categorized individually, and the highest risk
category was assigned to the study as a whole. Online
Appendix 2 presents the forms used to develop the
web-based questionnaires for the concept arm.
Ad hoc categorization procedure
In the ad hoc arm, assessors did not have specific cri-
teria to guide the categorization of clinical trial proto-
cols. Assessors had sets of regulatory requirements of
increasing strength for approval and conduct of clinical
trials (e.g. compensation of damages, application pro-
cedure, dossier content and safety reporting) that corre-
spond to each risk category. Assessors were asked to
appraise the clinical trial protocol, to consider the
potential risk to which participants would be exposed
and to indicate the category of regulatory requirements
that they considered most appropriate for approval
and conduct. As with the concept arm, no specific
training was provided besides a written general intro-
duction. Assessors applied the same categories as in the
concept arm: A, B or C for clinical trials with drugs; A
or C for clinical trials with medical devices; and A or B
for clinical trials with non-pharmacologic/non-device
interventions. Online Appendix 3 lists the regulatory
requirements by risk category and type of intervention.
Eligibility criteria of clinical trial protocols
Protocols were eligible if they had been approved by a
Swiss ethics committee between 2010 and 2011 and
described a clinical trial that fell within the definition
introduced by the new law: ‘Clinical trial means:
research project in which persons are prospectively
assigned to a health-related intervention in order to
investigate its effects on health or on the structure and
function on the human body’, with health-related inter-
vention defined as ‘a preventive, diagnostic, therapeu-
tic, palliative or rehabilitative measure investigated in a
clinical trial’.20 No restriction was applied on the type
of intervention that was evaluated or on the affiliation
of the sponsor (academic or commercial).
Identification of clinical trial protocols
Of the 13 Swiss ethics committees, 9 were asked to par-
ticipate in the study (Aargau, Bern, Basel, Lucerne,
Geneva, Ticino, St. Gallen, Lausanne and Zurich).
Ethics committees were asked to identify consecutive
clinical trials and to seek consent to participate in the
study from the corresponding sponsor. Ethics commit-
tees that received up to 100 submissions in 2011
(Aargau, Lucerne and Ticino) were asked to obtain
consent from 20–30 sponsors. All other ethics commit-
tees (Zurich, Bern, Basel, Lausanne, Geneva and St.
Gallen) were asked to obtain consent from 50 sponsors.
Sponsors who agreed to participate were asked to pro-
vide an electronic copy of the latest approved version
of the protocol or to allow the respective ethics com-
mittee to provide us with a copy.
Assessors of clinical trial protocols
There were three types of assessors categorizing proto-
cols: a contact person (per trial) on behalf of the clinical
trial sponsor (Sponsor), a member of each ethics com-
mittee (Ethics Committee) and an expert group (Expert
Group). The Expert Group was made up of a clinical
trial methodologist and physician from the clinical
trials unit at the University of Bern (CTU Bern) along
with three staff members of the Swiss Federal Office of
Public Health who contributed to drafting the Clinical
Trials Ordinance. All assessors were given the latest
approved version of the protocol, and all based their
categorization on the same version. Sponsors and cor-
responding clinical trial protocols were randomized to
the concept categorization or the ad hoc categorization
procedure arm. In a few cases, a sponsor was associated
with more than one protocol, but the randomized cate-
gorization approach was similar across protocols (clus-
ter randomization).
In the concept categorization arm, each clinical trial
protocol was categorized by the corresponding contact
person (Sponsor), a member of the ethics committee
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that had approved the clinical trial (Ethics Committee)
and two members of the expert group (Expert Group).
Each clinical trial protocol in the ad hoc categorization
arm was categorized by the corresponding Sponsor and
the Expert group. However, the Expert Group categor-
ized all clinical trial protocols, including those in the ad
hoc arm, using the concept categorization procedure.
Composition of the Expert Group varied and was
determined by availability (at least 2 out of 5 potential
persons). Several assessment meetings were held and
protocols assessed consecutively without any random
mechanism. Agreement between members of the Expert
Group was reached by consensus or by involvement of
a third group member, if necessary.
Data collection
Data were collected via a web-based electronic data cap-
turing system. Data collection processes were validated
and tested prior to the study. Assessors were given a
manual that explained the use of the system. Sponsors
and Ethics Committees were sent up to five e-mail
reminders during follow-up if they failed to respond.
Outcome measures
The primary outcome was the difference in categoriza-
tion agreement between the Expert Group and the
Sponsors across the arms as an indicator for consis-
tency of categorizations. The secondary outcome mea-
sure was categorization agreement between assessors
within the arms (inter-rater reliability).
Because of unexpectedly high disagreement between
assessors about the category and type of intervention
(see results), the Expert Group decided, post hoc, to re-
assess 89 clinical protocols. Six weeks after the first
assessment, the same persons who initially performed
the first assessment performed a second assessment of
79 randomly sampled protocols where initial agreement
was low and 10 randomly sampled protocols where ini-
tial agreement was high (intra-rater reliability).
Sample size
Sample size calculation was based on a simulation
approach for the primary outcome and for the inter-
rater reliability outcome. For the primary outcome, we
determined sample size to compare chance-corrected
agreements (Cohen’s kappa) between both arms. The
study size should have given the study a power of 80%,
with a two-sided type I error of 0.05 to detect a differ-
ence in kappas of 0.3 (0.8 in concept arm and 0.5 in ad
hoc arm). The simulation resulted in a sample size of
210 trial protocols (105 pro arm). After taking the
number of potential non-responders into consideration,
we set the resulting minimal sample size to 120 proto-
cols per study arm (240 overall).
To calculate the sample size for inter-rater reliabil-
ity, we only considered the concept arm. The 95% con-
fidence interval (CI) around the kappa coefficient of
0.8 should not be broader than 60.2; that is, a kappa
coefficient \ 0.6 should be excluded. The simulation
resulted in a sample size of 120 trial protocols. After
considering potential non-responders, we set the defini-
tive sample size for assessing inter-rater reliability at
140 trial protocols in the concept arm. The overall sam-
ple size for the study was therefore set to 260 trial pro-
tocols (140 for the concept and 120 for the ad hoc
arm).
Randomization, concealment and blinding
Trial protocols were randomized in three batches to the
concept or ad hoc arm, based on computer-generated
random numbers. An independent data manager, who
otherwise did not participate in the study, was responsi-
ble for the allocation. It was not possible to blind
assessors.
Statistical analysis
Cohen’s linear weighted kappa was used to quantify
agreement between categorizing bodies. Kappas and
raw proportions of agreement were calculated using
bootstrapping methods (N = 4000 repetitions), which
allowed us to control for the fact that some sponsors
evaluated multiple protocols. Kappa values from 0 to
0.4 were interpreted as low agreement; 0.40 to 0.75 were
fair to good; and larger than 0.75 were excellent. For
the primary outcome, we compared kappa values of
rater-pairs by a z-test on the bootstrapped data. For
stratified analyses, we compared subgroups by a z-test
on the bootstrapped data (test for interaction).
These analyses were done with Stata28 (StataCorp.
2011). Since Cohen’s kappa is an equivocal measure
of reliability, prone to biases since it is dependent
on the underlying distributions, we also computed
Krippendorff’s alpha as an alternate measure of relia-
bility. Since values of alpha and kappa were similar, we
report only Cohen’s kappa, as specified in the original
trial protocol. All CIs relate to the 95% level, and all
reported p-values are two-sided.
Results
Eight of the nine anticipated Swiss ethics committees
agreed to participate in the study (Aargau, Bern,
Geneva, Lucerne, St. Gallen, Ticino, Lausanne and
Zurich). We received 231 clinical trial protocols from
147 sponsors. Of these, 116 trial protocols were ran-
domly allocated to the concept categorization proce-
dure and 115 to the ad hoc procedure (Figure 1). Data
collection lasted from 1 October 2012 to 16 January
2013. Sponsors categorized 102 protocols with the
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concept procedure and 103 with the ad hoc procedure
(89%). Ethics Committees categorized 78 of 116 proto-
cols allocated to the concept procedure. The Expert
Group categorized 178 of 231 protocols. We included
142 trial protocols in the final analysis and excluded 89
(38.6%) for the following reasons: (1) studies did not
meet clinical trial definition according to the legislation,
(2) were duplicate studies or (3) other reasons (see
Online Appendix 4 for details). Table 1 summarizes
baseline characteristics of the trial protocols included
in the analysis. Most sponsors were affiliated with aca-
demia (76%), and the most common therapeutic area
of research was oncology (16%). Characteristics were
balanced across the two randomized arms. Figure 2
illustrates categorization by the different assessors. The
Sponsors categorized the majority of protocols into
category A, while the Expert Group categorized the
majority into category B. The Ethics Committee cate-
gorized most protocols either into category A or C.
Online Appendix 5 presents the final categorization by
type of assessor.
Trial category: agreement between assessors within
and between the concept and ad hoc arm
We compared agreement between assessors about the
trial category in two ways: (1) within each arm, between
the Sponsors and the Expert Group; and (2) between the
arms. Raw agreement within the concept arm was 0.74
and within the ad hoc arm 0.78. There were major dis-
agreements (e.g. if a trial was categorized by one body as
A or C and by the other as C or A, respectively) for 13
of 78 protocols in the concept arm (17%) and for 8 of 64
protocols in the ad hoc arm (12%). Chance-corrected
agreement between the Expert Group and Sponsors was
low within the concept arm (kappa: 0.27; 95% CI =
0.06–0.50) and the ad hoc arm (0.34; 95% CI = 0.10–
0.58). The difference between kappa values was 0.07 in
favour of the ad hoc procedure (p-value: 0.67). Neither
the type of sponsor, whether commercial or academic (p-
value for interaction: 0.74), nor the type of intervention
(p-value for interaction: 0.85) affected the degree of
agreement between assessors (Figure 3).
Inter-rater reliability: agreement between assessors
using the concept procedure
For the trial category, raw agreement between Ethics
Committees and the Expert Group was 0.81 and
between Ethics Committees and the Sponsor was 0.75.
Chance-corrected agreement was low between Ethics
Committees and the Expert Group (0.44; 95% CI =
0.22–0.64) and between Ethics Committees and the
Sponsor (0.35; 95% CI = 0.13–0.55). Neither the inter-
vention type nor the affiliation of the sponsor affected
the level of agreement between assessors (Figure 3).
Type of intervention evaluated in the clinical trial –
concept and ad hoc arm
The raw agreement on the type of intervention used in
the trial was relatively high between assessors: Expert
Group versus Sponsors was 0.82, Expert Group versus
Ethics Committees was 0.83 and Sponsors versus Ethics
Committees was 0.81. The chance-corrected agreement
on the type of intervention evaluated in a given trial
was generally moderate for the Expert Group versus
Sponsors (kappa: 0.68; 95% CI = 0.53–0.84), Expert
Group versus Ethics Committees (0.67; 95% CI =
0.52–0.82) and Ethics Committees versus Sponsors
(0.65; 95% CI = 0.49–0.80).
Intra-rater reliability: agreement between first and
second expert group’s categorization
Because of unexpectedly high disagreement between
assessors about the category and type of intervention,
the Expert Group decided, post hoc, to re-assess 89
Table 1. Characteristics of clinical trials protocols.
Characteristics Concept arm
(n = 78)
Ad hoc arm
(n = 64)
Type of intervention evaluated in the study,
as classified by the sponsor
IMP 46 (59) 33 (52)
MD 20 (26) 14 (22)
Mixed 3 (4) 5 (8)
Non-IMP/MD 9 (12) 12 (19)
Submission year
2010 1 (1) 0 (0)
2011 69 (89) 55 (86)
2012 8 (10) 9 (14)
Sponsor’s affiliation
Academia 57 (73) 51 (80)
Industry 21 (27) 13 (20)
Medical field of trial
Oncology/Haematology 15 (19) 8 (13)
Cardiology/Cardiac surgery 7 (9) 5 (8)
Intensive care medicine 7 (9) 6 (9)
Psychiatry/Neurology/
Neurosurgery
7 (9) 12 (19)
Otolaryngology 6 (8) 7 (11)
Infectious diseases 5 (6) 2 (3)
Rheumatology 5 (6) 0 (0)
Nephrology/Urology 4 (5) 3 (5)
Pharmacology 4 (5) 1 (2)
Dermatology 3 (4) 3 (5)
Endocrinology/
Nutritional medicine
3 (4) 2 (3)
Paediatrics 3 (4) 2 (3)
Gastroenterology/
Visceral surgery
1 (1) 5 (8)
Others 8 (10) 8 (13)
IMP: investigational medicinal product; MD: medical device.
These are absolute numbers (percentages in brackets).
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clinical protocols. For the trial category, raw agreement
between the categorization of the first and the second
Expert Group was high (0.95). After adjusting for
chance, the raw agreement was moderate (0.58; 95%
CI = 0.30–0.80).
For the type of intervention evaluated in the trial,
the agreement between the first and the second Expert
Groups’ categorization was high. Raw agreement was
0.95, and the chance-corrected agreement kappa was
0.93 (95% CI = 0.84–0.98). Online Appendix 6 shows
the agreement between the first and the second expert
group categorization.
Discussion
In this study, we assessed how accurately and consis-
tently clinical trials are categorized for regulatory pur-
poses using two different approaches: an approach
using criteria set forth in the new Swiss law on research
in humans (concept) or an intuitive approach (ad hoc).
We found no meaningful difference between the
approaches. The concept procedure, when implemented
without specific training, did not make categorization
of trial protocols more consistent than the ad hoc
approach. In the concept arm, major disagreements
were present in more than 15% of protocols.
We expected that categorization of clinical trials
would be straightforward with the presence of pre-
defined criteria. For example, we assumed that trials
investigating non-authorized drugs, falling into cate-
gory C, would be easy to categorize, even for persons
without specific training in the categorization proce-
dure. However, this study showed that even well-
structured categories for clinical trials are not consis-
tently interpreted and that training is required to clas-
sify them. There was considerable disagreement
between Sponsors, Ethics Committees and Experts
about the category of clinical trials. Furthermore, we
found disagreement between assessors about the type
of interventions that were evaluated in the trial. For
example, some assessors categorized homeopathic solu-
tions and food supplements as drugs and others as
non-drug chemical preparations.
Figure 2. Assessments of individual protocols by arm and group. Each pictogram represents an individual protocol assessed in the
trial across groups within each arm. Ethics committees did not assess protocols in the ad hoc arm.
Green protocols: assessed as category A; Yellow protocols: assessed as category B; Red protocols: assessed as category C; Grey protocols: no
assessment available.
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Clinical trial protocols included in this study were
written under the old law, which did not mandate an
explicit delineation of intervention types for trials.
Consequently, these protocols may be less clear than
protocols written under the new law, which sets higher
standards. Thus, we could expect fewer disagreements
in real-world situations after the new law is implemen-
ted. Our data do not indicate that specific aspects of
the categorization concept are in need of modification.
Our subjective impression was that completeness of
information required to categorize a trial was higher
for industry protocols as compared to protocols from
academia.
Limitations
This study was intended to inform policy-makers on
the applicability of the categorization criteria proposed
in the draft Clinical Trials Ordinance. Data collection
started right after the public consultation. In the major-
ity of cases, institutions and not individuals are invited
to participate in public consultations. However, we do
not know whether assessors randomized to the ad hoc
procedure took part in the public consultation before
our study commenced.
We excluded a large number of trial protocols (N =
89) from our final analysis. One of the reasons was that
Figure 3. Caterpillar plot of primary and secondary outcomes.
IMP: investigational medicinal product; MD: medical device
*p-values for interaction
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we could not contact Sponsors directly to ask them to
participate in the evaluation. The participating Ethics
Committees selected trial protocols that complied with
the new clinical trial definition and then contacted the
Sponsors to obtain their consent. We mostly excluded
protocols selected by the Ethics Committees because
they did not meet the new definition for clinical trials.
After completion of this study and during feedback
rounds, Ethics Committees acknowledged that they
might not have fully understood the new definition at
the time of selecting trial protocols for this study, and
thus may have misclassified some studies. Since the new
legislation was implemented without instructions or
training sessions, misclassifications of type of research
project may also happen in the future. Decisions to
exclude studies were taken without knowledge of any
categorization result of the sponsor or ethics commit-
tee. It is unlikely that these exclusions introduced bias,
but they did reduce sample size and power.
To reduce the workload for Ethics Committees, we
limited the required number of consenting sponsors to
20–50, based on the number of submissions they
received per year. Although Ethics Committees were
advised to select trial protocols consecutively, we were
unable to monitor the selection process. We do not
know how many Sponsors were contacted by the
Ethics Committee before they obtained the required
number of consenting Sponsors. We cannot exclude the
possibility of selection bias, although we think it is
unlikely that the sample of trial protocols is not repre-
sentative of all trial protocols in Switzerland.
Unfortunately, there was no central repository for clini-
cal research projects approved by Ethics Committees in
Switzerland, so we cannot evaluate representativeness.
This was in a sense a retrospective study since we
tested the categorization procedure on trial protocols
approved before the new law came into effect. This
might have contributed to the observed discrepancies.
In addition, the approval status of investigated drugs
or devices might have changed between the date that
the initial clinical trial was approved and the date we
conducted our study. Sponsors might have categorized
these trials based on the current approval status, while
the Expert Group used the approval status and label
information current at the time the clinical trial was ini-
tially approved. However, the number of such cases
was low.
We did not embed a qualitative study to formally
explore the subjective experience of participants
(Sponsors and Ethics Committees) as they used the
new categorization procedure. In retrospect, and given
the unexpectedly negative results of this study, we feel
that a nested qualitative study would have been useful.
Unfortunately, we were constrained in time and finan-
cial resources and could not pursue a more extensive
study. This was also the reason for not including ethics
committees in the randomized phase of the study which
would have helped to address our study question more
comprehensively. Finally, the pre-specified sample size
was not reached. Several of the preceding limitations
contributed to this. Most important among these was
the high number of protocols that had to be excluded
and the pre-specified numbers of sponsors to be con-
tacted by each ethics committee to reduce their work-
load. Nevertheless, our results even with this reduced
sample size are unlikely to change substantially with an
increased sample size.
Strengths of the study
To our knowledge, this is the first study to formally
evaluate the application of a new risk-based categoriza-
tion approach for clinical trials implemented at legisla-
tion level. Randomized controlled trials are optimal to
evaluate the effects of interventions and are well suited
for testing the risk-adapted categorization procedure of
clinical trials proposed by the new Swiss legislation.
Although we excluded a high number of protocols, our
sample size was sufficient to exclude a relevant agree-
ment with the new categorization procedure as imple-
mented in this study. We actively engaged the main
stakeholders in clinical research in Switzerland and
raised their awareness for the upcoming changes intro-
duced by the new legislation. We also provided an
opportunity for sponsors, members of ethics commit-
tees, academic institutions, the pharmaceutical industry
and government bodies to consider the details, implica-
tions and consequences of implementing the risk-
adapted classification criteria and adapted regulations.
As such, our study provided valuable new information
about the effects of the new legislation to the concerned
community.
Implications for further research
The concept of enacting risk-based regulations for
human research is still new. More research is needed to
illuminate aspects of this approach and to assess the
extent to which risk-based regulations serve their pur-
pose. We offer a feasible and useful approach to gath-
ering reliable data about important aspects of drafted
regulations before they are implemented. Comparable
studies in other countries, with different legal systems,
or in other fields of research should seek to overcome
the limitations of our approach.
Implications for legislation on clinical research
The risk-adapted categorization procedure defined in
the new Swiss law is based on recommendations from
the OECD working group.14 The categorization criteria
are broadly comparable with the MRC/DH/MHRA
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concept applied in the United Kingdom15 and that pro-
posed in the current version of the revised EU regula-
tion.18 Therefore, the limitations encountered during
this study might also be applicable to EU countries.
Conclusion and legislation recommendations
Categorization procedures based on strict criteria are
not necessarily an improvement over intuitive categori-
zation, especially when sponsors use instead informally
an ad hoc approach based on comprehensive informa-
tion on the resulting consequences of each category.
Failure to properly implement the procedure may be
due to lack of training. More guidance and directed
training for sponsors and ethics committees might
ensure that the categorization procedure of the ordi-
nance is followed more strictly. In particular, we believe
that developing a binding protocol template, thereby
forcing sponsors to provide explicitly all relevant infor-
mation, would improve the reliability of the categoriza-
tion. We also suggest that agreement between sponsors
and ethics committees be assessed periodically after the
regulation is enacted.
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